AR114946A2 - Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas - Google Patents
Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismasInfo
- Publication number
- AR114946A2 AR114946A2 ARP190100029A ARP190100029A AR114946A2 AR 114946 A2 AR114946 A2 AR 114946A2 AR P190100029 A ARP190100029 A AR P190100029A AR P190100029 A ARP190100029 A AR P190100029A AR 114946 A2 AR114946 A2 AR 114946A2
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- piperazin
- pyrimidin
- dichloro
- urea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente tecnología proporciona formas cristalinas anhidras e hidratadas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea, polimorfos amorfos y cristalinos anhidros de su sal de ácido monofosfórico, y la sal de clorhidrato, incluyendo su dihidrato. La presente tecnología proporciona además métodos para la preparación de las diferentes formas, composiciones que las contienen, y métodos para el tratamiento mediante el empleo de las mismas. Reivindicación 1: Una forma cristalina anhidra del compuesto de la fórmula (1), en donde la forma cristalina anhidra tiene un patrón de difracción en polvo de rayos-X que comprende un pico característico, en términos de 2q, a aproximadamente 12º.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26715509P | 2009-12-07 | 2009-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114946A2 true AR114946A2 (es) | 2020-11-11 |
Family
ID=43983750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104472A AR079257A1 (es) | 2009-12-07 | 2010-12-03 | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| ARP190100029A AR114946A2 (es) | 2009-12-07 | 2019-01-07 | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104472A AR079257A1 (es) | 2009-12-07 | 2010-12-03 | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9067896B2 (es) |
| EP (1) | EP2509963B1 (es) |
| JP (2) | JP5714024B2 (es) |
| KR (1) | KR101787784B1 (es) |
| CN (5) | CN111100078A (es) |
| AR (2) | AR079257A1 (es) |
| AU (1) | AU2010328391B2 (es) |
| BR (1) | BR112012013784B1 (es) |
| CA (1) | CA2781431C (es) |
| CL (1) | CL2012001480A1 (es) |
| DK (1) | DK2509963T3 (es) |
| EC (1) | ECSP12012026A (es) |
| ES (1) | ES2562462T3 (es) |
| GT (1) | GT201200181A (es) |
| HR (1) | HRP20160126T1 (es) |
| HU (1) | HUE026983T2 (es) |
| IL (1) | IL220012B (es) |
| JO (1) | JO3061B1 (es) |
| MA (1) | MA33849B1 (es) |
| MX (1) | MX2012006562A (es) |
| MY (1) | MY158333A (es) |
| NZ (3) | NZ700778A (es) |
| PE (1) | PE20121499A1 (es) |
| PH (2) | PH12012501146A1 (es) |
| PL (1) | PL2509963T3 (es) |
| RU (1) | RU2572848C2 (es) |
| SG (1) | SG10201408063SA (es) |
| SI (1) | SI2509963T1 (es) |
| TN (1) | TN2012000263A1 (es) |
| TW (1) | TWI526440B (es) |
| WO (1) | WO2011071821A1 (es) |
| ZA (1) | ZA201203612B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013144339A1 (en) * | 2012-03-30 | 2013-10-03 | Novartis Ag | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| ES2892423T3 (es) | 2013-03-15 | 2022-02-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| RU2715708C2 (ru) * | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
| ES2745983T3 (es) * | 2013-12-13 | 2020-03-04 | Novartis Ag | Formas de dosificación farmacéutica |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| JP6503450B2 (ja) | 2015-03-25 | 2019-04-17 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| WO2016151501A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
| SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2016189472A1 (en) | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| SG10201913213WA (en) | 2015-12-17 | 2020-03-30 | Eisai R&D Man Co Ltd | Therapeutic agent for breast cancer |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| CN108884097B (zh) * | 2016-05-20 | 2021-05-28 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| AU2017315357B2 (en) * | 2016-08-23 | 2022-12-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| US11440903B2 (en) | 2017-11-01 | 2022-09-13 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
| CN111712245A (zh) | 2018-03-28 | 2020-09-25 | 卫材R&D管理有限公司 | 用于肝细胞癌的治疗剂 |
| CN119241541A (zh) | 2018-05-04 | 2025-01-03 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP4045484A4 (en) * | 2019-10-14 | 2023-09-06 | Hutchison Medipharma Limited | SALTS OF A COMPOUND AND CRYSTALLINE FORMS THEREOF |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL303500A (en) * | 2020-12-18 | 2023-08-01 | Qed Therapeutics Inc | Methods of treating achondroplasia |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| WO2022271933A1 (en) | 2021-06-23 | 2022-12-29 | Kimtron, Inc. | System and method for ultra-close proximity irradiation of rotating biomass |
| CA3244743A1 (en) * | 2022-03-18 | 2025-06-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | SALT OF A SIX-LINK AMINO-SUBSTITUTE NITRIC HETEROCYCLIC COMPOUND, CRYSTALLINE FORM THEREIN, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| EP4676486A1 (en) | 2023-03-06 | 2026-01-14 | QED Therapeutics, Inc. | Methods of treating skeletal dysplasias |
| WO2025061013A1 (zh) * | 2023-09-18 | 2025-03-27 | 上海润石医药科技有限公司 | 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用 |
| WO2025090870A1 (en) | 2023-10-27 | 2025-05-01 | Qed Therapeutics, Inc. | Infigratinib and metabolites thereof for use in methods of treating skeletal disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101242843A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| CA2629136C (en) * | 2005-11-08 | 2016-03-08 | Choongwae Pharma Corporation | .alpha.-helix mimetics and method relating to the treatment of cancer stem cells |
| WO2007071752A2 (en) * | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| CA2720888A1 (en) * | 2008-04-29 | 2009-11-05 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
-
2010
- 2010-12-03 AR ARP100104472A patent/AR079257A1/es not_active Application Discontinuation
- 2010-12-05 JO JOP/2010/0433A patent/JO3061B1/ar active
- 2010-12-06 ES ES10788479.3T patent/ES2562462T3/es active Active
- 2010-12-06 KR KR1020127017618A patent/KR101787784B1/ko active Active
- 2010-12-06 US US13/514,308 patent/US9067896B2/en active Active
- 2010-12-06 SI SI201031119A patent/SI2509963T1/sl unknown
- 2010-12-06 WO PCT/US2010/059108 patent/WO2011071821A1/en not_active Ceased
- 2010-12-06 DK DK10788479.3T patent/DK2509963T3/en active
- 2010-12-06 EP EP10788479.3A patent/EP2509963B1/en active Active
- 2010-12-06 NZ NZ700778A patent/NZ700778A/en unknown
- 2010-12-06 PE PE2012000772A patent/PE20121499A1/es active IP Right Grant
- 2010-12-06 SG SG10201408063SA patent/SG10201408063SA/en unknown
- 2010-12-06 CN CN201911273119.5A patent/CN111100078A/zh active Pending
- 2010-12-06 PH PH1/2012/501146A patent/PH12012501146A1/en unknown
- 2010-12-06 MX MX2012006562A patent/MX2012006562A/es active IP Right Grant
- 2010-12-06 BR BR112012013784-0A patent/BR112012013784B1/pt active IP Right Grant
- 2010-12-06 NZ NZ624315A patent/NZ624315A/en unknown
- 2010-12-06 CN CN2010800550783A patent/CN102639510A/zh active Pending
- 2010-12-06 RU RU2012128351/04A patent/RU2572848C2/ru active
- 2010-12-06 CN CN201911278014.9A patent/CN111269186A/zh active Pending
- 2010-12-06 NZ NZ600070A patent/NZ600070A/en unknown
- 2010-12-06 PH PH12014502593A patent/PH12014502593A1/en unknown
- 2010-12-06 TW TW099142438A patent/TWI526440B/zh active
- 2010-12-06 HR HRP20160126T patent/HRP20160126T1/hr unknown
- 2010-12-06 CN CN201510484635.8A patent/CN105061332A/zh active Pending
- 2010-12-06 HU HUE10788479A patent/HUE026983T2/en unknown
- 2010-12-06 CA CA2781431A patent/CA2781431C/en active Active
- 2010-12-06 CN CN201911272657.2A patent/CN111100077A/zh active Pending
- 2010-12-06 PL PL10788479T patent/PL2509963T3/pl unknown
- 2010-12-06 MY MYPI2012002222A patent/MY158333A/en unknown
- 2010-12-06 JP JP2012543183A patent/JP5714024B2/ja active Active
- 2010-12-06 AU AU2010328391A patent/AU2010328391B2/en active Active
-
2012
- 2012-05-17 ZA ZA2012/03612A patent/ZA201203612B/en unknown
- 2012-05-24 IL IL220012A patent/IL220012B/en active IP Right Grant
- 2012-05-25 TN TNP2012000263A patent/TN2012000263A1/en unknown
- 2012-06-06 CL CL2012001480A patent/CL2012001480A1/es unknown
- 2012-06-07 GT GT201200181A patent/GT201200181A/es unknown
- 2012-06-26 MA MA35005A patent/MA33849B1/fr unknown
- 2012-07-05 EC ECSP12012026 patent/ECSP12012026A/es unknown
-
2015
- 2015-01-20 JP JP2015008550A patent/JP6019142B2/ja active Active
-
2019
- 2019-01-07 AR ARP190100029A patent/AR114946A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| PE20120083A1 (es) | Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a | |
| AR112227A2 (es) | Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma | |
| CL2012001348A1 (es) | Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. | |
| ECSP17084267A (es) | Pirazolo[1,5a]pirimidinas como agentes antivirales | |
| AR080490A1 (es) | FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| CU24099B1 (es) | Derivados de sulfonamida para el tratamiento del dolor | |
| UA115320C2 (uk) | Інгібітори кінази | |
| MY160785A (en) | Manufacturing process for pyrimidine derivatives | |
| ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| ECSP11011383A (es) | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| PH12012500992A1 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| AR090209A1 (es) | Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden | |
| BR112013028789A2 (pt) | processo | |
| CU20110108A7 (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
| BR112017012926A2 (pt) | precursores de ácido n-acético de alanina, processo de preparação de precursores, uso de precursores, e processo de hidrólise dos precursores | |
| AR077692A1 (es) | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo | |
| PE20091344A1 (es) | Arilindenopirimidinas como antagonistas del receptor a2a de adenosina | |
| NI201200194A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen | |
| AR068349A1 (es) | Polimorfos de agonistas de prostaglandinas y procedimientos para fabricar los mismos | |
| AR088943A1 (es) | Acido 2-[(3,5-difluoro-3-metoxi-1,1-bifenil-4-il)amino]nicotinico para el tratamiento de psoriasis | |
| CY1117185T1 (el) | Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων | |
| ECSP099729A (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FC | Refusal |